• Marta Baber, Priya Bapat, Gail Nichol, and Gideon Koren.
• Division of Clinical Pharmacology & Toxicology, Department of Pediatrics, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, M5G 1X8, Canada.
• Pharmacogenomics. 2016 Jan 1; 17 (1): 75-93.

AimsOpioids are commonly prescribed for postpartum pain. Yet, providing adequate pain relief, while ensuring that the mother and her breastfeeding infant are protected from adverse events can be challenging. The objective of this systematic review was to identify the role of opioid pharmacogenetics in analgesia and adverse events among patients being treated for postpartum pain, along with their breastfeeding infants.MethodsA comprehensive search of the literature was conducted in seven databases on June 3-4, 2015. Two reviewers independently screened studies for eligibility, extracted data and evaluated study quality using the Newcastle-Ottawa Scale.ResultsAmong the 2082 papers retrieved from the search, 17 were included in the review. These 17 papers consisted of various study designs, opioids, polymorphisms and patient outcomes. This systematic review reveals that CYP2D6, OPRM1 A118G, UGT2B7 C802T and ABCB1 G2677AT may contribute to postpartum analgesia or adverse events.ConclusionThese findings may assist in personalizing care for patients receiving opioids during the postpartum period.

26 keywords...

hide…